Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with CIETAI and Radiotherapy in Central Squamous NSCLC
NCT05892237Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Objective Response Rate 2 at 2 years. Started Jul 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05892237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892237.